How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Breast Cancer Screening Test Market
- By Screening Method: Mammography, Breast MRI, Ultrasound, Molecular Breast Imaging (MBI), Digital Breast Tomosynthesis (3D Mammography)
- By Technology: Film Mammography, Digital Mammography, Contrast-Enhanced Mammography, Automated Breast Ultrasound (ABUS), Positron Emission Mammography (PEM)
- By End User: Hospitals, Diagnostic Centers, Breast Cancer Screening Clinics, Ambulatory Surgical Centers, Mobile Screening Units
- By Screening Population: Average Risk Women, High Risk Women (Genetic Predisposition), Women with Dense Breast Tissue, Post-Treatment Surveillance Patients, Women Undergoing Routine Health Check-ups
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Mammography leads By Screening Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Breast Cancer Screening Test Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Screening Method 5
Technology 5
End User 5
Screening Population 5
Companies profiled
Hologic Inc.
GE Healthcare
Siemens Healthineers
Fujifilm Holdings Corporation
Canon Medical Systems Corporation
Philips Healthcare
Carestream Health
Koninklijke Philips N.V.
Delphinus Medical Technologies Inc.
Mammotome (Devicor Medical Products
Inc.)
Planmed Oy
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GE Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Fujifilm Holdings Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Canon Medical Systems Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Philips Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Carestream Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Koninklijke Philips N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Delphinus Medical Technologies Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mammotome (Devicor Medical Products
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Inc.)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Planmed Oy
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Hitachi Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Neusoft Medical Systems
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Dilon Technologies Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Civco Medical Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,893M by 2033 · 4.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Mammography45.5
- Breast MRI12.0
- Ultrasound14.3
- Molecular Breast Imaging (MBI)10.7
- Digital Breast Tomosynthesis (3D Mammography)17.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,129M → $1,672M · 5.0%
Europe$787.2M → $1,090M · 4.2%
Asia Pacific$718.8M → $925.5M · 3.2%
Latin America$445.0M → $591.7M · 3.6%
Middle East and Africa$342.3M → $492.9M · 4.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.522026
4.532027
4.542028
4.562029
4.572030
4.582031
4.592032
4.612033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Hologic Inc.26.8
- GE Healthcare10.6
- Siemens Healthineers6.6
- Fujifilm Holdings Corporation10.4
- Canon Medical Systems Corporation4.2
- Philips Healthcare13.3
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Screening Method21.7%
Technology13.8%
End User29.1%
Screening Population35.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.0
- Europe22.8
- Asia Pacific19.4
- Latin America12.4
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Hologic Inc. | 98 | 77 | 81 | 75 | 97 | 98 | 88 |
| GE Healthcare | 91 | 73 | 84 | 71 | 82 | 79 | 80 |
| Siemens Healthineers | 65 | 85 | 64 | 72 | 70 | 74 | 72 |
| Fujifilm Holdings Corporation | 79 | 78 | 61 | 68 | 74 | 77 | 73 |
| Canon Medical Systems Corporation | 70 | 71 | 58 | 70 | 51 | 68 | 65 |
| Philips Healthcare | 58 | 62 | 69 | 63 | 56 | 60 | 61 |
| Carestream Health | 59 | 46 | 62 | 45 | 48 | 55 | 53 |
| Koninklijke Philips N.V. | 44 | 42 | 46 | 53 | 44 | 36 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Hologic Inc.
- GE Healthcare
- Siemens Healthineers
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Hologic Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| GE Healthcare | ◐ | ◐ | ✓ | − | ◐ | ✓ |
| Siemens Healthineers | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Fujifilm Holdings Corporation | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Canon Medical Systems Corporation | ✓ | ◐ | − | ◐ | − | ◐ |
| Philips Healthcare | − | − | − | − | ◐ | − |
| Carestream Health | − | − | − | − | − | ◐ |
| Koninklijke Philips N.V. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Hologic Inc.88
2GE Healthcare80
3Fujifilm Holdings Corporation73
4Siemens Healthineers72
5Canon Medical Systems Corporation65
6Philips Healthcare61
7Carestream Health53
8Koninklijke Philips N.V.44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Hologic Inc.GE Healthcare
Challenger2
Strong scale, closing on the leaders.
Siemens HealthineersFujifilm Holdings Corporation
Contender2
Focused players with pockets of strength.
Canon Medical Systems CorporationPhilips Healthcare
Niche2
Specialists in a single segment or region.
Carestream HealthKoninklijke Philips N.V.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Screening Method in North America, then scale across Breast Cancer Screening Test Market — a $102M beachhead inside a $1.53B market.
Beachhead (SOM)$102Mobtainable near-term
Serviceable (SAM)$588Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Mammography
Best fit — highest urgency & budget in Screening Method.
Economic buyer75 fit
Breast MRI
Strong fit — clear ROI and a fast path to value.
End user64 fit
Ultrasound
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Screening Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel25%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Screening Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Breast Cancer Screening Test Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified26%
Evaluation12%
Closed-won6%
$13.1KCAC
$64KLTV
4.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Breast Cancer Screening Test Market is a durable-growth opportunity — $1.03B by 2033, compounding at 8.5%.
TAM · 2025$538Mtoday
TAM · 2033$1.03Bforecast
CAGR8.5%2027–2033
Cumulative$6.86Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.03BTotal addressable market
SAM$383MServiceable available market
SOM$75MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.5% CAGR
Demand compounds through 2033, outpacing GDP across Screening Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Screening Method moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.03BLarge & growingTAM by 2033 at 8.5% CAGR
$383MServiceable nowreachable with today’s model
$75MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$805MBear5.5% CAGR
$1.03BBase8.5% CAGR
$1.32BBull11.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Breast Cancer Screening Test Market — a $3.21B market by 2033. Plan: grow share from 7.5% to 16.0%.
Market size · 2033$3.21Btotal addressable
Market CAGR9.7%2027–2033
Target share16.0%from 7.5% today
Revenue ambition$513Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.5% | 16.0% | At risk |
| Revenue | $231M | $513M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 33.5% | 40.2% | On track |
| Customer retention | 90.8% | 93.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Screening Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Screening Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $73M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Screening Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Breast Cancer Screening Test Market conversation — a $10.5B market you can size, segment and defend in minutes.
Market size · 2033$10.5Btotal opportunity
Growth8.7%CAGR to 2033
Addressable buyers1,235+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Screening Method
Goal Grow share in Screening Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 3 mopayback period
$98K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Hologic Inc.GE HealthcareSiemens HealthineersFujifilm Holdings CorporationCanon Medical Systems CorporationPhilips HealthcareCarestream HealthKoninklijke Philips N.V.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Breast Cancer Screening Test Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Breast Cancer Screening Test Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Breast Cancer Therapeutics Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportBreast Cancer, Ovarian Cancer & Prostate Cancer Screening & Diagnostic Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBreast Diagnostic Imaging Market
Market size, share, segmentation and regional forecast.
$901M market · 2025 base year
View reportBreast Enhancement Cream Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportBreast Falling Number Analyzer Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportBreast Form Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBreast Formsxa0 Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportBreast Imaging System Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportBreast Infrared Detector Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportBreast Localization System Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportBreast Magnetic Resonance Imaging (MRI) Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBreast Mask Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.